XML 109 R74.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Research and development | $ 796.2 |  |  | $ 473.1 | $ 1,219.6 | $ 910.4
Other | 41.6 |  |  | 79.0 | 131.6 | 166.9
Collaboration profit (loss) sharing | 26.5 |  |  | (5.6) | 47.3 | (5.6)
Product, net | 2,639.7 |  |  | $ 2,466.0 | 5,019.8 | $ 4,775.4
Bristol-Myers Squibb |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Research and development |  |  |  |  | 300.0 |
Additional milestone payments | 410.0 |  |  |  | 410.0 |
iPerian |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Additional milestone payments | 490.0 |  |  |  | 490.0 |
Developmental Milestone Payment | 60.0 |  |  |  | $ 60.0 |
AbbVie |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Biogen share of co-promotion profits or losses |  |  |  |  | 50.00% |
AbbVie | U.S. |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Other | 3.9 |  |  |  | $ 9.8 |
AbbVie | Rest of world |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Collaboration profit (loss) sharing |  |  |  |  | 1.3 |
Ionis Pharmaceuticals [Member] |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
License Fee |  |  | $ 75.0 |  |  |
Ionis Pharmaceuticals [Member] | SPINRAZA |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Additional milestone payments | 40.0 |  |  |  | 40.0 |
Ionis Pharmaceuticals [Member] | SPINRAZA | U.S. |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Product, net | 194.8 |  |  |  | 241.2 |
Ionis Pharmaceuticals [Member] | SPINRAZA | Rest of world |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Product, net | $ 8.1 |  |  |  | 9.1 |
Acquired and in-licensed rights and patents | SPINRAZA |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Increase in acquired and in-licensed rights and patents |  | $ 60.0 |  |  | $ 50.0 |
Minimum | Ionis Pharmaceuticals [Member] | SPINRAZA |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Royalty payments per the collaboration |  |  |  |  | 11.00% |
Maximum | Ionis Pharmaceuticals [Member] | SPINRAZA |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Royalty payments per the collaboration |  |  |  |  | 15.00% |

X
- Definition Additional milestone payment. + References No definition available. + Details
Name: | biib_AdditionalMilestonePayment
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Biogen share of co-promotion profits or losses + References No definition available. + Details
Name: | biib_Biogenshareofcopromotionprofitsorlosses
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration profit (loss) sharing + References No definition available. + Details
Name: | biib_Collaborationprofitlosssharing
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Developmental Milestone Payment + References No definition available. + Details
Name: | biib_DevelopmentalMilestonePayment
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License Fee + References No definition available. + Details
Name: | biib_LicenseFee
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of royalties as per collaboration. + References No definition available. + Details
Name: | biib_PercentageOfRoyaltiesAsPerCollaboration
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a),(d)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_OtherSalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_IPerianMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_AbbVieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |